JWH-133, a Selective Cannabinoid CB₂ Receptor Agonist, Exerts Toxic Effects on Neuroblastoma SH-SY5Y Cells

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2016 Feb 5

PMID 26842917

Citations 6

Authors

Jakub Wojcieszak

Wojciech Krzemien

Jolanta B Zawilska

Affiliations

Soon will be listed here.

Abstract

Endocannabinoid system plays an important role in the regulation of diverse physiological functions. Although cannabinoid type 2 receptors (CB2) are involved in the modulation of immune system in peripheral tissues, recent findings demonstrated that they are also expressed in the central nervous system and could constitute a new target for the treatment of neurodegenerative disorders. At present, very little is known about the potential effects of CB2-mimetic drugs on neuronal cells. This study aimed to examine whether JWH-133, a selective CB2 receptor agonist, affects the survival of SH-SY5Y neuroblastoma cell line, a widely used experimental in vitro model to study mechanisms of toxicity and protection in nigral dopaminergic neurons. Cell viability was assessed using two complementary methods: MTT test measuring mitochondrial activity and LDHe test indicating disruption of cell membrane integrity. In addition, cell proliferation was measured using BrdU incorporation assay. JWH-133 (10-40 μM) induced a concentration-dependent decrease of SH-SY5Y cell viability and proliferation rate. Using AM-630, a reverse agonist of CB2 receptors, as well as Z-VAD-FMK, a pan-caspase inhibitor, we demonstrated that the cytotoxic effect of JWH-133 presumably was not mediated by activation of CB2 receptors or by caspase pathway. Results of this work suggest that agonists of CB2 receptors when administered in multiple/high doses may induce neuronal damage.

Citing Articles

Identification of a Cannabinoid Receptor 2 Allosteric Site Using Computational Modeling and Pharmacological Analysis.

Farooq Z, Delre P, Iliadis S, Mangiatordi G, Contino M, Howell L ACS Pharmacol Transl Sci. 2025; 8(2):423-434.

PMID: 39974643 PMC: 11833715. DOI: 10.1021/acsptsci.4c00547.

Maternal Dietary Deficiencies in Folic Acid and Choline Change Metabolites Levels in Offspring after Ischemic Stroke.

Anwar F, Mosley M, Jasbi P, Chi J, Gu H, Jadavji N Metabolites. 2024; 14(10).

PMID: 39452933 PMC: 11509810. DOI: 10.3390/metabo14100552.

Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells.

Gado F, Ferrisi R, Di Somma S, Napolitano F, Mohamed K, Stevenson L Molecules. 2022; 27(9).

PMID: 35566369 PMC: 9101764. DOI: 10.3390/molecules27093019.

Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.

Correia B, Fernandes J, Botica M, Ferreira C, Quintas A Medicines (Basel). 2022; 9(3).

PMID: 35323718 PMC: 8950629. DOI: 10.3390/medicines9030019.

Molecular signaling of synthetic cannabinoids: Comparison of CB1 receptor and TRPV1 channel activation.

Andersen H, Walsh K Eur J Pharmacol. 2021; 907:174301.

PMID: 34224700 PMC: 8374946. DOI: 10.1016/j.ejphar.2021.174301.

References

Knasmuller S, Mersch-Sundermann V, Kevekordes S, Darroudi F, Huber W, Hoelzl C . Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology. 2004; 198(1-3):315-28. DOI: 10.1016/j.tox.2004.02.008. View

Tomiyama K, Funada M . Cytotoxicity of synthetic cannabinoids found in "Spice" products: the role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line. Toxicol Lett. 2011; 207(1):12-7. DOI: 10.1016/j.toxlet.2011.08.021. View

Koller V, Auwarter V, Grummt T, Moosmann B, Misik M, Knasmuller S . Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8. Toxicol Appl Pharmacol. 2014; 277(2):164-71. DOI: 10.1016/j.taap.2014.03.014. View

Liu Q, Pan C, Hishimoto A, Li C, Xi Z, Llorente-Berzal A . Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav. 2009; 8(5):519-30. PMC: 3389515. DOI: 10.1111/j.1601-183X.2009.00498.x. View

Gomez-Galvez Y, Palomo-Garo C, Fernandez-Ruiz J, Garcia C . Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2015; 64:200-8. DOI: 10.1016/j.pnpbp.2015.03.017. View

Sierra S, Luquin N, Rico A, Gomez-Bautista V, Roda E, Dopeso-Reyes I . Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct. 2014; 220(5):2721-38. PMC: 4549378. DOI: 10.1007/s00429-014-0823-8. View

Garcia M, Cinquina V, Palomo-Garo C, Rabano A, Fernandez-Ruiz J . Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci Lett. 2014; 587:1-4. DOI: 10.1016/j.neulet.2014.12.003. View

Huffman J, Liddle J, Yu S, Aung M, Abood M, Wiley J . 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem. 2000; 7(12):2905-14. DOI: 10.1016/s0968-0896(99)00219-9. View

Aymerich M, Rojo-Bustamante E, Molina C, Celorrio M, Sanchez-Arias J, Franco R . Neuroprotective Effect of JZL184 in MPP(+)-Treated SH-SY5Y Cells Through CB2 Receptors. Mol Neurobiol. 2015; 53(4):2312-9. DOI: 10.1007/s12035-015-9213-3. View

10.

Pacher P, Kunos G . Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J. 2013; 280(9):1918-43. PMC: 3684164. DOI: 10.1111/febs.12260. View

11.

Pahlman S, Mamaeva S, Meyerson G, Mattsson M, Bjelfman C, Ortoft E . Human neuroblastoma cells in culture: a model for neuronal cell differentiation and function. Acta Physiol Scand Suppl. 1990; 592:25-37. View

12.

Schmole A, Lundt R, Ternes S, Albayram O, Ulas T, Schultze J . Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model. Neurobiol Aging. 2014; 36(2):710-9. DOI: 10.1016/j.neurobiolaging.2014.09.019. View

13.

Van Sickle M, Duncan M, Kingsley P, Mouihate A, Urbani P, Mackie K . Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005; 310(5746):329-32. DOI: 10.1126/science.1115740. View

14.

Xie H, Hu L, Li G . SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J (Engl). 2010; 123(8):1086-92. View

15.

Onaivi E, Ishiguro H, Gu S, Liu Q . CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol. 2011; 26(1):92-103. PMC: 3388033. DOI: 10.1177/0269881111400652. View

16.

Pertwee R, Howlett A, Abood M, Alexander S, Di Marzo V, Elphick M . International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010; 62(4):588-631. PMC: 2993256. DOI: 10.1124/pr.110.003004. View

17.

Taylor L, Christou I, Kapellos T, Buchan A, Brodermann M, Gianella-Borradori M . Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor. Sci Rep. 2015; 5:10682. PMC: 4451551. DOI: 10.1038/srep10682. View

18.

den Boon F, Chameau P, Schaafsma-Zhao Q, van Aken W, Bari M, Oddi S . Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci U S A. 2012; 109(9):3534-9. PMC: 3295302. DOI: 10.1073/pnas.1118167109. View

19.

Koller V, Ferk F, Al-Serori H, Misik M, Nersesyan A, Auwarter V . Genotoxic properties of representatives of alkylindazoles and aminoalkyl-indoles which are consumed as synthetic cannabinoids. Food Chem Toxicol. 2015; 80:130-136. DOI: 10.1016/j.fct.2015.03.004. View

20.

Tomiyama K, Funada M . Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death. Toxicol Appl Pharmacol. 2013; 274(1):17-23. DOI: 10.1016/j.taap.2013.10.028. View